8-K: Moleculin Biotech Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech has completed its End of Phase 2 meeting with the FDA regarding its Annamycin clinical trial for AML, with positive remission rates reported.

Summary

• Moleculin Biotech has concluded its End of Phase 2 (EOP2) meeting with the FDA for its Phase 1B/2 clinical trial of Annamycin combined with Cytarabine (AnnAraC) for treating Acute Myeloid Leukemia (AML).
• The trial includes both first-line therapy and treatment for patients who have relapsed or are refractory to initial treatment.
• The company expects to receive official minutes from the FDA by the end of Q3 2024 and will report the meeting outcomes at that time.
• The EOP2 meeting was supported by second-line treatment results from the ongoing MB-106 clinical trial.
• 22 subjects were enrolled in the trial, with 20 completing efficacy evaluations.
• Of the 20 subjects, 9 (45%) achieved a composite complete remission (CRc), including 8 (40%) with complete remission (CR) and 1 with complete remission with incomplete blood count recovery (CRi).
• In the second-line setting, 5 out of 10 subjects achieved a CR (50%) and 6 achieved a CRc (60%).
• For the 13 subjects in the first or second line treatment, 7 achieved a CR (54%) and 8 achieved a CRc (62%).
• The median duration of remission (mDOR) for the 9 subjects who achieved a CRc is approximately 7 months and is still increasing.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, and Orphan Drug Designation for soft tissue sarcoma.
• It also has Orphan Drug Designation from the European Medicines Agency (EMA) for relapsed or refractory AML.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and regulatory progress, suggesting a favorable outlook for the company's lead drug candidate. The completion of the EOP2 meeting and the reported remission rates are encouraging.

Positives

• The completion of the EOP2 meeting with the FDA is a positive step for the Annamycin development program.
• The clinical trial showed a 45% composite complete remission rate (CRc) across all evaluated subjects.
• The second-line treatment group showed a 50% complete remission (CR) rate and a 60% composite complete remission (CRc) rate.
• Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA, which can expedite the approval process.
• The drug also has Orphan Drug Designation from the EMA, expanding its potential market.

Risks

• The company is still awaiting official minutes from the FDA, and the final outcome of the EOP2 meeting is not yet fully known.
• Clinical trial data is preliminary and subject to change.
• The company's forward-looking statements are subject to risks and uncertainties, as detailed in their SEC filings.

Future Outlook

The company anticipates reporting the outcomes of the EOP2 meeting upon receipt of official minutes from the FDA, expected by the end of Q3 2024. They also plan to continue the clinical development program for Annamycin in AML.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that the company had a very productive meeting with the FDA and looks forward to reporting its outcome before the end of August.
• The Moleculin team, along with regulatory advisors and key opinion leaders, discussed the MB-106 safety and efficacy clinical findings and proposed next steps for the AML clinical development program with the FDA.

Industry Context

This announcement is significant for the oncology space, particularly in the treatment of AML, a challenging cancer with limited effective therapies. The positive remission rates reported for Annamycin could position it as a valuable treatment option if approved.

Comparison to Industry Standards

• The reported 45% composite complete remission rate (CRc) in the MB-106 trial is promising when compared to standard AML treatments, which often have lower remission rates, particularly in relapsed or refractory cases.
• For example, standard chemotherapy regimens for relapsed/refractory AML often achieve CR rates in the 20-30% range, making the 50% CR rate in the second-line setting of the MB-106 trial a notable improvement.
• Companies like Jazz Pharmaceuticals with Vyxeos and Agios Pharmaceuticals with Tibsovo are also developing treatments for AML, but Annamycin's unique mechanism of action and reported efficacy could provide a competitive edge.
• The 7-month median duration of remission (mDOR) is also a key metric, as many AML treatments have short remission durations, and a longer mDOR suggests a more durable response.

Stakeholder Impact

• Shareholders may react positively to the reported clinical trial results and regulatory progress.
• Patients with AML may benefit from a new treatment option if Annamycin is approved.
• The company's employees may be motivated by the positive developments in the clinical program.

Next Steps

• The company will await official minutes from the FDA regarding the EOP2 meeting.
• Moleculin will report the outcomes of the EOP2 meeting by the end of Q3 2024.
• The company will continue the clinical development program for Annamycin in AML.

Key Dates

Keywords

Annamycin, AML, FDA, Clinical Trial, Oncology, Moleculin Biotech, MB-106, AnnAraC, Remission, Orphan Drug Designation